DiaMedica Therapeutics Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation Canada (Federal Level)
Business Address 301 CARLSON PARKWAY, MINNEAPOLIS, MN, 55305
Mailing Address 301 CARLSON PARKWAY, MINNEAPOLIS, MN, 55305
Phone (763) 496-5454
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2025
-$24.44M
Net Income
$56.11M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 30, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 8-K Current report of material events | January 5, 2026 | View on SEC |
| 8-K Current report of material events | December 18, 2025 | View on SEC |
| 4 Insider stock transaction report | December 8, 2025 | View on SEC |
Annual Reports
10-K March 30, 2026
- Advancing DM199, a synthetic KLK1 protein, for stroke, preeclampsia, and fetal growth restriction.
- Positive clinical results from a preeclampsia study in South Africa showing safety and efficacy.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.